FDAnews
www.fdanews.com/articles/208215-sanofi-and-gsk-next-generation-covid-19-vaccine-booster-shows-promise-against-omicron

Sanofi and GSK Next-Generation COVID-19 Vaccine Booster Shows Promise Against Omicron

June 14, 2022

Sanofi and GSK’s next-generation COVID-19 vaccine booster, which was developed to target the Beta variant of the SARS-CoV-2 virus, has demonstrated a significant antibody response against the Omicron variants in two clinical trials.

In one phase 3 study, participants who received the booster shot after being primed with a messenger RNA (mRNA) COVID-19 vaccine showed a 40-fold increase in antibodies against the Omicron BA.1 variant.

In a separate study, the new booster dose also demonstrated increased antibody responses against the Omicron BA.1 variant compared with Pfizer-BioNTech’s booster and Sanofi-GSK’s original booster, Sanofi said.

Global regulatory authorities are currently reviewing the original version of the booster, but the companies plan to submit the data supporting the next-generation booster within weeks, and are aiming to make the booster available later this year.

View today's stories